Finally, rapamycin was used for targeting TLR4, which triggered immune escape of tumor cells and inhibited the TLR4-activated NF-κB signaling pathway, uncovering a novel mechanism behind the antitumor effects of rapamycin [125]. Here, NFKB1 is linked to neoplasm.